Calcium-antagonist drugs

New England Journal of Medicine

Volumn 341, Issue 19, 1999, Pages 1447-1457

  Abernethy, Darrell R ^a,c   Schwartz, Janice B ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Clinical Pharmacology   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BEPRIDIL; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CARDIAC GLYCOSIDE; DILTIAZEM; FELODIPINE; ISRADIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; VERAPAMIL;

ADVERSE DRUG REACTION; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; HEART INFARCTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; SUBARACHNOID HEMORRHAGE;

ANGINA PECTORIS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION;

EID: 0033523858     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199911043411907     Document Type: Review

References (96)

1. Freher M, Challapalli S, Pinto JV, Schwartz J, Bonow RO, Gheorgiade M. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Probl Cardiol 1999;24:236-40.
2. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 1994;74:365-507.
3. Hockermon GH, Peterson BZ, Johnson BD, Catterall WA. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol 1997;37:361-96.
4. Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 1992;44: 363-76.
5. 2+ channels. Trends Pharmacol Sci 1998;19:108-15.
6. Reuter H, Scholz H. The regulation of the calcium conductance of cardiac muscle by adrenaline. J Physiol (Lond) 1977;264:49-62.
7. Kameyama M, Hofmann F, Trautwein W. On the mechanism of β-adrenergic regulation of the Ca channel in the guinea-pig heart. Pflugers Arch 1985;405:285-93.
8. Tsien RW, Giles W, Greengard P. Cyclic AMP mediates the effects of adrenaline on cardiac Purkinje fibers. Nat New Biol 1972;240:181-3.
9. 2+-channel currents in single vascular smooth muscle cells. Pflugers Arch 1987;409:7-12.
10. + currents in mammalian gastric smooth muscle cells. Science 1985;229:269-72.
11. Nelson MT, Standen NB, Brayden JE, Worley JF III. Noradrenaline contracts arteries by activating voltage-dependent calcium channels. Nature 1988;336:382-5.
12. Ohya Y, Sperelakis N. Involvement of a GTP-binding protein in stimulating action of angiotensin II on calcium channels in vascular smooth muscle cells. Circ Res 1991;68:763-71.
13. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci U S A 1989;86:3915-8.
14. Andrawis NS, Craft N, Abernethy DR. Calcium antagonists block angiotensin II-mediated vasoconstriction in humans: comparison with their effect on phenylephrine-induced vasoconstriction. J Pharmacol Exp Ther 1992;261:879-84.
15. Andrawis NS, Gilligan J, Abernethy DR. Endothelin-I-mediated vasoconstriction: specific blockade by verapamil. Clin Pharmacol Ther 1992;52: 583-9.
16. Andrawis NS, Abernethy DR. Verapamil blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 1992;183:767-73.
17. Schmitt R, Clozel JP, Iberg N, Buhler FR. Mibefradil prevents neointima formation after vascular injury in rats: possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 1995;15:1161-5.
18. 4+ blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996;93:5478-82.
19. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 1981;68:1366-9.
20. Lichtlen PR, Hugenholtz PG, Rafflenbuel W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-13.
21. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.
22. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest I992;90:1871-8.
23. Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993;348: 332-7.
24. Pichard L, Gillett G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990;18:711-9.
25. Guengerich FP, Brian WR, Iwasaki M, Sari M-A, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991;34: 1838-44.
26. Abernethy DR, Schwartz JB. Pharmacokinetics of calcium antagonists under development. Clin Pharmacokinet 1988;15:1-14.
27. Kroemer HR, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992;260:1052-7.
28. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55:509-17.
29. Morel N, Buryi V, Feron O, Gomez J-P, Christen M-O, Godfraind T. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol 1998;125:1005-12.
30. 2+ channel splice variants. J Biol Chem 1995;270:10540-3.
31. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46. [Erratum, Arch Intern Med 1998;158:573.]
32. Staessen JA, Thijs L, Fagard RH, et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998;32:410-6.
33. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-5.
34. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-7.
35. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995;155:2150-6.
36. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995;123: 888-9.
37. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996;276:785-91.
38. Jariwalla AG, Anderson EG. Production of ischaemic cardiac pain by nifedipine. BMJ 1978;1:1181-2.
39. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80:1453-8.
40. Schwartz JB, Caputo G, Abbott J. Early experience with dobutamine stress testing and cardiac cine-tomographic imaging in the elderly: antianginal effects of nifedipine-GITS. J Am Geriatr Soc 1993;41:967-74.
41. Byington RP, Craven TE, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997; 350:1075-6.
42. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
43. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
44. Epstein M. The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk. Am J Cardiol 1997;79: Suppl 10A:9-19.
45. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.
46. Stone PH. Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol 1987;59: 101B-115B.
47. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propanolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differencial effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 1990;82:1962-72.
48. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm: experience in 127 patients. N Engl J Med 1980;302: 1269-73.
49. Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta-blockers for optimal antianginal therapy. Clin Cardiol 1994;17:415-21.
50. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both: report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 1986;56:400-13.
51. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation 1995;92:1079-82.
52. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.
53. Hohnloser SH, Kuck KH. Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PLAF trial. Pacing Clin Electrophysiol 1997;20:1989-92.
54. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am J Cardiol 1997; 79:1198-202.
55. Uematsu D, Greenberg JH, Hickey WF, Reivich M. Nimodipine attenuates both increase in cytosolic free calcium and histologic damage following focal cerebral ischemia and reperfusion in cats. Stroke 1989;20:1531-7.
56. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989;298:636-42.
57. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJA. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-7.
58. Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987;59:84B-94B.
59. The Multicentcr Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
60. Ishikawa K, Nakai S, Takenaka T, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997;95:2368-73.
61. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II - DAVIT II. Am J Cardiol 1990;66:779-85.
62. Jespersen CM. The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. Eur Heart J 1993;14:540-5.
63. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996;77:365-9.
64. The DEFIANT-II Research Group. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy: results of the DEFIANT-II study. Eur Heart J 1997;18:31-40.
65. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997;79:738-41.
66. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
67. Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-9.
68. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438-47.
69. Olsen JH, Sørensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091-4.
70. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998;16:119-24.
71. Rosenberg L, Rao S, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;279:1000-4.
72. Schinkel AH, Wagenaar E, Mol CAAM, von Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
73. Doppenschmitt S, Langguth F, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H. Characterization of binding properties to human P-glycoprotein: development of a [3H] verapamil radioligand-binding assay. J Pharmacol Exp Ther 1999;288:348-57.
74. Hunter J, Hirst BH. Intestinal secretion of drugs: the role of P-glycoprotein, and related drug efflux systems in limiting oral drug absorption. Adv Drug Delivery Rev 1997;25:129-57.
75. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
76. Abernethy DR. Grapefruits and drugs: when is statistically significant clinically significant? J Clin Invest 1997;99:2297-8.
77. Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982;65:998-1003.
78. Kuhlmann J. Effects of quinidine, verapamil and nifedipine on the pharmacokinetics and pharmacodynamics of digoxin during steady state conditions. Arzneimittelforschung 1987;37:545-8.
79. Lee TH, Salomon DR, Rayment CM, Antman EM. Hypotension and sinus arrest with exercise-induced hyperkalemia and combined verapamil/propranolol therapy. Am J Med 1986;80:1203-4.
80. Abernethy DR. Pharmacological properties of combination therapies for hypertension. Am J Hypertens 1997;10:Suppl:13S-16S.
81. Price WA, Giannini AJ. Neurotoxicity caused by lithium-verapamil synergism. J Clin Pharmacol 1986;26:717-9.
82. Buhler FR. Age and cardiovascular response adaptation: determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers. Hypertension 1983;5:Suppl III:III-94-III-100.
83. Abernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: altered electrocardiographic and hypotensive responses. Ann Intern Med 1986;105:329-36.
84. Schwartz JB, Abernethy DR. Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension. Am J Cardiol 1987;59:1111-7.
85. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990; 48:76-86.
86. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists: an update. Clin Pharmacokinet 1992;22:416-33.
87. Schwartz JB. Calcium antagonists in the elderly: a risk-benefit analysis. Drugs Aging 1996;9.24-36.
88. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994;23-.145-58.
89. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. [Erratum, N Engl J Med 1993;330:152.]
90. Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985;249:F619-F629.
91. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43:808-14.
92. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
93. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-50.
94. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998;21: 104-10.
95. Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKDPS 39. BMJ 1998;317:713-20.
96. Millard RW, Grupp G, Grupp IL, DiSalvo J, DePover A, Schwartz A. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine,